Allergan drops Valeant-Ackman insider trading lawsuit

Carly Helfand Allergan–now owned by Actavis–and its former hostile suitors, Valeant and Bill Ackman's Pershing Square, are putting the past behind them. FiercePharma ...

Safety scare with AstraZeneca’s diabetes drug could shake up the DPP-4 field

Damian Garde The FDA raised some alarming concerns tied to AstraZeneca's Onglyza ahead of a committee meeting to discuss the safety of so-called DPP-4 inhibitors, sounding a worrying ...

AstraZeneca’s Onglyza ‘mortality’ risks noted by FDA reviewers

Eric Palmer FDA staff reviewers have raised serious concerns about the safety of AstraZeneca's Onglyza ahead of an advisory committee review Tuesday, which could result in a recommendation ...

Virtual biotechs a hit with investors and, increasingly, buyers

Damian Garde Biotech venture capitalists have increasingly embraced the virtual model, seeding companies with promising assets, tiny staffs and a willingness to outsource. Now, as Reuters ...

CEO Dekkers’ legacy at Bayer? Embracing risk, à la its American rivals

Carly Helfand Marijn Dekker's time in the Bayer CEO chair is winding down, and the Dutchman has a couple of big items left on his to-do list before he turns over the reins. But ...

Plotting a course for True North, biotech CEO steps up with a $35M round

John Carroll Nancy Stagliano has a very clear idea of how to plot a course for True North. Eighteen months ago the biotech CEO raised $ 30 million for iPierian and split its assets ...

Shire’s Lialda, Gattex are hedge funder’s latest patent targets

Tracy Staton Hedge fund manager Kyle Bass has struck out at drug patents once again. Just weeks after challenging two patents on an Acorda Therapeutics drug, Bass asked the U.S. Patent ...

High-flying immuno-oncology player Adaptimmune pitches $150M IPO

John Carroll Adaptimmune Therapeutics CEO James Noble once told FierceBiotech that the biotech had only 1 million pounds in the bank back in June. But in quick order the Oxford company ...

Flexus founders regroup after $1.25B Bristol-Myers deal

Damian Garde Flexus Biosciences turned heads around the industry when Bristol-Myers Squibb signed a $ 1.25 billion deal to buy the fledgling biotech in February, but the company's ...

J&J, Novartis lead pharma companies by market cap

Carly Helfand Which Big Pharma companies have the biggest market caps in the industry? The Motley Fool has a breakdown of the top 10, but we'll give you a hint: The list ...

Pfizer shutters vaccine sales business in China after Prevenar setback

Carly Helfand As it beefs up its vaccines business, Pfizer's looking to bolster revenue from the top-selling Prevenar family of shots. But on that front, it's come up against ...

UPDATED: GlaxoSmithKline to create new vaccines hub, uprooting R&D groups in Cambridge, Philly

John Carroll GlaxoSmithKline is setting up a global vaccines hub in Rockville, MD, in the wake of its big asset swap with Novartis. And the move will force hundreds of staffers in Cambridge, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS